What is Tirzepatide?
Tirzepatide with Imperative Healthcare N.P., LLC is available with or without Glycine and B12.
Tirzepatide is a once-weekly injectable medication that targets two key hormones to help regulate blood sugar and appetite. It enhances insulin sensitivity, slows down digestion, and reduces hunger. This promotes effective weight loss and better metabolic control.
How Tirzepatide Works for Weight Loss
- GLP-1 (glucagon-like peptide-1) Agonist: Reduces appetite and increases feelings of fullness after eating.
- GIP (glucose-dependent insulinotropic polypeptide) Agonist: Enhances the body's ability to break down sugar and fat by stimulating insulin release after eating. This helps regulate blood sugar levels and may also affect fat metabolism as well as reduce appetite.
Pricing Transparency
Pricing includes your follow up visit, medication, and supplies!
- Dose <10mg/week - $400/4-week supply
- Dose 10mg/week - $490/4-week supply
- Dose 12.5-15mg/week - Contact Us for More Info!
**Save 10% when booking a 3-month bundle**
Tirzepatide vs. Semaglutide
While both tirzepatide and semaglutide are effective for weight loss and diabetes management, there are key differences that might make tirzepatide a preferable option for some individuals:
- Dual Hormone Action:Tirzepatide’s unique approach of targeting two hormones offers a broader range of metabolic benefits, potentially leading to greater weight loss compared to drugs that target only GLP-1, like semaglutide.
- Enhanced Weight Loss Results: Clinical studies have shown that tirzepatide can lead to significantly greater weight loss than semaglutide, making it an attractive option for individuals with higher weight loss goals.
- Versatile Treatment Options: The ability to impact both blood sugar and body weight makes tirzepatide a multifunctional tool for managing both diabetes and obesity.
Are Injections Safe for Everyone?
The short answer is yes! Weight loss with semaglutide and tirzepatide is safe for most people, there are always some people it should not be prescribed to:
- Clients with uncontrolled thyroid disease.
- Clients with a personal or family history of C-Cell tumors, medullary thyroid carcinoma (MTC), or multiple neoplasia syndrome type 2 (MEN2).
- Clients with pancreatic disease.
- Clients who are pregnant, breast feeding, or planning to be pregnant soon.
- Clients with a BMI less than 27 and have no other metabolic illnesses (high blood pressure, elevated cholesterol, etc.).
- Have not achieved desired weight loss results with other treatments like semaglutide.
